ATG-112 / Antengene - LARVOL DELTA

ATG-112 (ALPPL2 x CD3 TCE) (PRNewswire) - "A global first-in-class ALPPL2 x CD3 targeted TCE being developed for the treatment of gynecologic tumor, non-small cell lung cancer, and pancreatic ductal adenocarcinoma. The Company has nominated a preclinical candidate (PCC) in January 2026."

Pipeline update • Gynecologic Cancers • Non Small Cell Lung Cancer • Pancreatic Ductal Adenocarcinoma